Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people: A position statement of Primary Care Diabetes Europe
Hambling, C. E.; Khunti, K.; Cos, X.; Wens, J.; Martinez, L.; Topsever, P.; Del Prato, S.; Sinclair, A.; Schernthaner, G.; Rutten, G.; Seidu, S.
(2019) Primary Care Diabetes, volume 13, issue 4, pp. 330 - 352
(Article)
Abstract
Diabetes in later life is associated with a range of factors increasing the complexity of glycaemic management. This position statement, developed from an extensive literature review of the subject area, represents a consensus opinion of primary care clinicians and diabetes specialists. It highlights many challenges facing older people living with
... read more
type 2 diabetes and aims to support primary care clinicians in advocating a comprehensive, holistic approach. It emphasises the importance of the wishes of the individual and their carers when determining glycaemic goals, as well as the need to balance intended benefits of treatment against the risk of adverse treatment effects. Its ultimate aim is to promote consistent high-quality care for older people with diabetes.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Frailty, Glycaemic goals, Hypoglycaemia, Older people, Type 2 diabetes, Internal Medicine, Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics
ISSN: 1751-9918
Publisher: Elsevier BV
Note: Funding Information: GEHMR has received grants from Sanofi and personal fees from Novo Nordisk. Funding Information: This position statement was initiated and completed independently by the Primary Care Diabetes Study Group of the European Association for the Study of Diabetes with full funding from Primary Care Diabetes Europe (PCDE). PCDE has received corporate gold sponsorship from Eli Lilly and AstraZeneca and silver sponsorship from Roche. This project was conceived by CEH and developed from her MSc project, undertaken at the University of Leicester, Leicester Diabetes Centre, with supervision from SS and KK. The clinicians from the Leicester Diabetes Centre led the formation of the Faculty, the development and generation of the content of this position statement and contributed to the writing and co-ordination of the project on behalf of PCDE. We would like to acknowledge and thank Nicola Milne and Guusje Neijens, who provided a diabetes nursing perspective. We would also like to thank all those who contributed to the Patient & Public Involvement in Research focus group at the Leicester Diabetes Centre, Leicester, UK and professionals who gave feedback at the PCDE Professional Conference in Barcelona, April 2018 and Diabetes UK for giving permission to refer to the End of Life Diabetes Care Clinical Recommendations in this position statement. C.E.H would like to acknowledge support from the Department of Public Health and Primary Care, School of Clinical Medicine, Cambridge, UK and the National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) East of England programme. K.K and S.S would like to acknowledge support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care-East Midlands (NIHR CLAHRC-EM) and the NIHR Leicester Biomedical Research Centre. The views expressed here are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. Medical writing support was provided by a team of writers from OmniaMed SB, funded by PCDE. Funding Information: This position statement was initiated and completed independently by the Primary Care Diabetes Study Group of the European Association for the Study of Diabetes with full funding from Primary Care Diabetes Europe (PCDE) . PCDE has received corporate gold sponsorship from Eli Lilly and AstraZeneca and silver sponsorship from Roche . Publisher Copyright: © 2018
(Peer reviewed)